Navigation Links
Shire plc - Statement re: Media Speculation
Date:7/11/2014

DUBLIN, July 11, 2014 /PRNewswire/ --


Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. 

Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon.  Shire confirms it has held a meeting with representatives of AbbVie.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

A further update will be made when appropriate.  Shareholders are strongly advised to take no action in relation to AbbVie's proposal.  There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.

A copy of this announcement will be available at http://www.shire.com.  The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Notes to editors 

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

http://www.shire.com

 

CONTACTS 

Shire 

Stephanie Fagan

+1-201-572-9581

FTI Consulting (Media Adviser to the Company) 

Andrew Lorenz (London)

+44-77-7564-1807

Ben Atwell (London)

+44-20-3727-1000

David B. Roady (New York)

+1-212-850-5600

Robert Stanislaro (New York)

+1-212-850-5600



'/>"/>
SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Launches Online Educational Resource Center for US Patients with Ulcerative Colitis
2. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
3. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
4. Shire to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
5. Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
6. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. Shire Reaches Agreement in Principle With U.S. Government
9. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
10. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
11. Shire Changes its NASDAQ Ticker Symbol to SHPG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Basel, Switzerland (PRWEB) , ... ... ... leading provider of advanced software solutions for pharmaceutical research and development (R&D), ... project-based expertise in omic data analysis and interpretation for the rapidly evolving ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, Inc. ... enhancing productivity in aquaculture and a majority-owned subsidiary of ... it has completed the listing of its common shares ... subscription from Intrexon. "AquaBounty,s listing on NASDAQ ... broaden our exposure to the U.S. markets as we ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, was today awarded ... The awards program is based entirely on merit and decided upon by a ...
Breaking Biology Technology:
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
Breaking Biology News(10 mins):